|
David Armistead has over 18 years of pharmaceutical and biotechnology industry experience, during which his work has led to the identification of a number of drug candidates currently in human clinical trials in the treatment of cancer and autoimmune diseases. Previously, Armistead held the position of Vice President and Site Head for the Amgen Cambridge Research Center, where he oversaw all aspects of East Coast research activities for Amgen Inc. Prior to joining Amgen, Armistead co-founded and served as Vice President of Research and Development and Chief Scientific Officer for Kinetix Pharmaceuticals, where he researched the rational design of selective kinase inhibitors for the treatment of inflammation and cancer. Armistead was also a founding member of Vertex Pharmaceuticals, where he served in various positions including Project Head for Immunosuppressive Research and Development. He has also held positions at Merck Sharp and Dohme Research Laboratories (Merck and Co., Inc.) and Yale University. Armistead earned his Ph.D. in synthetic organic chemistry from the University of South Carolina and his M.S. and B.A. from Virginia Polytechnic Institute. | 